Skip to main content
. Author manuscript; available in PMC: 2009 Sep 16.
Published in final edited form as: Circulation. 2008 Sep 2;118(12):1259–1267. doi: 10.1161/CIRCULATIONAHA.108.770669

Figure 1. Niacin/statin treatment remodels the HDL3 proteome in six subjects with CAD.

Figure 1

HDL3 was isolated from 6 CAD subjects before and after 1 year of therapy with sustained-release niacin and atorvastatin and tryptic digests of HDL3 analyzed by LC-MS/MS. Proteins identified as differentially expressed before (black bars) and during treatment (empty bars) by spectral counting were quantified by extracted ion chromatograms, using the area under the curve (AUC) of the chromatograms. Average AUCs for two representative peptides from each protein are shown (left column) along with a sample chromatograph for a peptide from each protein (right column). The peptides analyzed were: (A,B) PLTP, AGA (AGALQLLLVGDK3+) and SVV (SSVDELVGIDYSLM3+) (C,D) apoF, SGV (SGVQQLIQYYQDQK3+) and SYD (SYDLDPGAGSLEI); (E,F) apoJ, LFD (LFDSDPITVTVPVEVSR2+) and VTT (VTTVASHTSDSDVPSGVTEVVVK3+); (G,H) apoE, AAT (AATVGSLAGQPLQER2+) and GEV (GEVQAMLGQSTEELRVR3+). The effect of treatment on protein levels was determined by using all peptides quantified for each protein by repeated measures two-way analysis of variance. P<0.05 for all proteins other than apoA-I (P=0.44) and apoC-II (P=0.06). Shown are mean±SEM.